We have investigated whether the neuronal nicotinic subunit ␤3 can participate in the assembly of functional recombinant receptors. Although ␤3 is expressed in several areas of the central nervous system, it does not form functional receptors when expressed heterologously together with an ␣ or another ␤ nicotinic subunit. We inserted into the human ␤3 subunit a reporter mutation (V273T), which, if incorporated into a functional receptor, would be expected to increase its agonist sensitivity and maximum response to partial agonists. Expressing the mutant ␤3 V273T in Xenopus oocytes together with both the ␣3 and the ␤4 subunits resulted in the predicted changes in the properties of the resulting nicotinic receptor when compared with those of ␣3␤4 receptors. This indicated that some of the receptors incorporated the mutant ␤3 subunit, as part of a "triplet" ␣3␤4 ␤3 receptor. The proportion of triplet receptors was dependent on the ratios of the ␣3:␤4:␤3 cRNA injected. We conclude that, like the related ␣5 subunit, the ␤3 subunit can form functional receptors only if expressed together with both ␣ and ␤ subunits.
Molecular cloning has brought to light an unsuspected multitude of subunits that are the building blocks of ligand-gated ion channels. Our understanding of the functional importance of this diversity is still very incomplete. We need to know which subunits can co-assemble, which ones actually do so in native tissue, and whether the properties of the receptors assembled from different subunit combinations are different in a physiologically meaningful way (1) .
A good example is that of the neuronal nicotinic acetylcholine (ACh) 1 receptors, for which as many as 11 different subunits (named ␣2-␣9 and ␤2-␤4) have been cloned. Heterologous expression has shown that, apart from ␣7, ␣8, and ␣9, which can form homomeric receptors, functional receptors require the co-expression of an "␣/␤" pair of subunits, i.e. ␣2-4 with ␤2 or ␤4 (2). The ␣6 subunit contributes to functional receptors if expressed with ␤2, with ␤4 or, as a "triplet," with ␣3 and ␤4 (3, 4) . Neither ␣5 nor ␤3 can form ␣/␤ "pair" receptors: ␣5 can form functional triplet receptors with ␣3␤2, ␣3␤4, or ␣4␤2 (detectable because of changes in agonist sensitivity, macroscopic desensitization, and channel conductance (5-7)). Although the ␤3 subunit was discovered more than 9 years ago (8) , its role remains obscure. It could be that ␤3 is a transcribed pseudogene (i.e. a non-functional gene) or that the ␤3 subunit coassembles into a functional nicotinic receptor only with another, yet to be identified, subunit. Alternatively, it is conceivable that ␤3, like the ␣5 subunit, could form functional receptors only if expressed in a triplet combination. This is supported by the high similarity between the ␣5 and ␤3 subunit (80% amino acid sequence similarity, i.e. identical amino acids and conservative substitutions) and they have been classified in a separate group within the neuronal nicotinic receptor family (9) .
However, the number of potential triplet combinations that would have to be screened is large, because ␤3 can be immunoprecipitated from at least five different brain regions, where it is present in neurones that express a variety of other subunits (2, 10, 11) . Unless the effects of ␤3 on receptor properties are as striking as those of ␣5, the range of tests to be carried out is likely to be extensive. In addition, there may be differences in triplet receptor assembly between oocytes and cell lines (12) , e.g. ␣3␤4 receptors expressed in oocytes differ in their channel properties from ␣3␤4 receptors expressed in HEK293 cells (13) . Until it has been established which of the heterologous expression systems is closer to native neurones for each combination, it is desirable that these tests should be carried out both in oocytes and in cell lines.
We have investigated which ␤3-containing triplet combinations assemble by inserting into the ␤3 subunit a reporter mutation, V273T. This mutation converts the hydrophobic residue in the middle of the pore-lining second transmembrane domain (TM2) into a hydrophilic residue. In the nicotinic receptors in which this type of mutation has been tested (␣7 (14) and mouse muscle (15, 16) ), in the ␣1␤2␥2 ␥-aminobutyric acid receptor (17) , and in the 5HT 3 receptor (18) , it resulted in a pronounced leftward shift of the agonist concentration-response curve. This shift was found to increase regularly with the number of mutated subunits incorporated (15) and is likely to result from changes in the gating equilibrium constant due to destabilization of the closed state, although there may also be a contribution by the desensitized state becoming conducting (14) .
We found that expressing ␤3 V273T together with the ␣3 and ␤4 subunits in Xenopus oocytes changes the pharmacological properties of the ␣3␤4 recombinant nicotinic receptor, suggesting that the ␤3 V273T subunit is incorporated into a functional ␣3␤4␤3 V273T receptor.
EXPERIMENTAL PROCEDURES
Construction of cRNA for Oocyte Expression-cDNAs for the human ␣3, ␤3, and ␤4 (GenBank TM accession numbers Y08418, Y08417, and Y08416, respectively), containing only coding sequences and an added Kozak consensus sequence (GCCACC) immediately upstream of the start codon (19) , were subcloned into the pSP64GL vector, which con-tains 5Ј-and 3Ј-untranslated Xenopus ␤-globin regions (20) . The V273T mutation was inserted in ␤3 using the QuickChange TM Site-directed Mutagenesis Kit (Stratagene; mutagenesis primer used: 5Ј-GTCGACA-GAAAAGACTTCTTCGATAACGGAGAATGG-3Ј), and the full-length sequence was verified. All four cDNA/pSP64GL plasmids were linearized immediately downstream of the 3Ј-untranslated ␤-globin sequence, and cRNA was transcribed using the SP6 Mmessage Mmachine Kit (Ambion). The quality and quantity were checked by RNA gel electrophoresis and comparison with RNA concentration and size markers.
Expression in Xenopus Oocytes-Mature female Xenopus laevis frogs were anesthetized by immersion in a 0.2% solution (pH 5.6) of ethyl m-aminobenzoate (methanesulfonate, Tricaine, Sigma) and killed by decapitation and destruction of the brain and the spinal cord. The ovarian lobes were dissected into small clumps of 5-10 oocytes, treated with collagenase (Sigma IA; 245 collagen digestion units/ml) for 75 min, and defolliculated manually. Healthy stage V-VI oocytes were selected for injection of cRNA coding for the nicotinic subunits to be expressed (23 nl, 1.2 pg of cRNA in total per oocyte). cRNA ratios were 1:1 for ␣3␤4, 1:1:1 and 1:1:20 for ␣3␤4 ϩ ␤3
V273T , and 1:1:20 for ␣3␤4 ϩ ␤3
WT injections. The injection was carried out with a Drummond Nanoject injector. Oocytes were incubated in Barth's solution at 18°C for 2 days, then stored at 4 -6°C until needed for electrophysiological recording (up to 2 weeks later). Electrophysiological Recording-Current responses were obtained by two-electrode voltage clamp recording at a holding potential of Ϫ70 mV (Axoclamp 2B, Axon Instrument), with electrodes filled with 3 M KCl. Agonists solutions (ACh chloride and (Ϫ)-nicotine hydrogen tartrate, both from Sigma) were freshly prepared in modified Ringer's solution from frozen aliquots of stock and bath-applied (approximately 5 ml/min) to elicit inward currents which were recorded on a chart for subsequent analysis. Agonist responses were obtained at 5-min intervals, and a standard ACh concentration (50 M) was applied every third response. The responses to 50 M ACh were used to correct for rundown of response amplitude during the experiment, by linear interpolation.
Solutions-Barth's solution for oocyte culture had a composition of (mM) NaCl (88), KCl (1), MgCl 2 (0.82), CaCl 2 (0.77), NaHCO 3 (2.4), Tris-HCl (15), with 50 units ml Ϫ1 penicillin and 50 g ml Ϫ1 streptomycin, pH 7.4. The solution was sterilized by filtration (0.22 m pore filter, Millex-GV, Millipore).
The modified Ringer solution for oocyte recording contained (mM): NaCl (150), KCl (2.8), MgCl 2 (2), HEPES (10), atropine sulfate (0.5 M), pH 7.2 adjusted with NaOH.
Data Analysis-A full concentration-response curve to ACh was obtained for each oocyte included in this study. Analysis of the results was carried out by fitting each concentration-response curve separately (by equally weighted least squares, CvFit program by David Colquhoun) with the Hill equation I ϭ I max (x nH /(EC 50 nH ϩ x nH )) where I max is the maximum response to the agonist, x the agonist concentration, n H the Hill coefficient, and EC 50 the agonist concentration that produces 50% of the maximum response.
RESULTS AND DISCUSSION
We have expressed in Xenopus oocytes the ␣3␤4 combination alone or together with wild type ␤3 (␤3 WT ) or mutant ␤3 (␤3 V273T ). Addition of cRNA for the ␤3 WT subunit to ␣3 and ␤4 did not produce a detectable shift in the ACh concentrationresponse curve (see Fig. 1 and Table I ), but when ␤3
V273T was added instead of the ␤3 WT , a pronounced leftward shift in the ACh concentration-response curve was observed. This suggests that the mutated ␤3 subunit is incorporated into the expressed receptor.
The next question is, what proportion of the receptors expressed after injection of ␣3, ␤4, and ␤3 do actually contain ␤3? The results in Table I and Fig. 1 were all obtained by injection of cRNAs for these subunits in a ratio of 1:1:20. We can obtain an estimate of the proportion of current due to triplet receptors by fitting the ACh concentration-response curves with the sum of two Hill equations, the first of which is supposed to represent pair receptors and therefore has its EC 50 and Hill slope (n H ) fixed at the values already determined in oocytes expressing ␣3␤4 alone (180 M and 1.81, respectively (Table I) ). Fig. 1B shows four concentration-response curves from oocytes injected with ␣3, ␤4, and ␤3
V273T cRNAs in the ratio 1:1:1. The fit shown (see legend) gives an estimate of the fraction of current carried by triplet channels as 61 Ϯ 4.3% (n ϭ 4) with 2-unit likelihood intervals (roughly 95% confidence) of 54% to 73%. The EC 50 and n H values estimated for the mutant triplet receptor (2nd component in Fig. 1B) were 37.7 Ϯ 3.6 M and 1.31 Ϯ 0.09 for the 1:1:1 injections with ␤3 V273T , very close to the values obtained by a two-component fit of the 1:1:20 injections (41.8 Ϯ 6.5 M, 1.22 Ϯ 0.06). When the cRNAs were injected in the ratio 1:1:20, fitting two components produced only a slight improvement (0.5 log likelihood units) over a single component, so it was not possible to estimate the fraction attributable to the second component (for either ␤3
WT or ␤3 V273T ), but the results were consistent with a large proportion of the receptors being triplets.
A change in gating for receptors containing the mutant subunit would also be expected to change the agonist efficacy, the maximum open probability, and therefore the maximum WT and ␤3 V273T . For display all responses for each subunit combination were pooled after each response had been normalized to the fitted maximum for each individual oocyte (CvFit program, n ϭ 7, 5, and 9 for ␣3␤4, ␣3␤4␤3
WT , and ␣3␤4␤3 V273T , respectively). The values in Table I were obtained by averaging estimates found by fitting separate concentration-response curves, but direct fitting of the pooled curves shown here gives results that are not greatly different. B, two-component fits to concentrationresponse curves on four oocytes injected with ␣3, ␤4, ␤3
V273T cRNAs in a ratios of 1:1:1. The four curves were fitted simultaneously with the sum of two Hill equations. There were 10 free parameters, namely the maximum response for each curve, the EC 50 for the second component (that presumed to represent triplet receptors) for each curve, the Hill coefficient for the second component (assumed to be the same for all curves), and the fraction of the total maximum response attributable to the second component (also assumed to be the same for all curves). agonist response. Whether the change in maximum response is big enough to be detected will depend on whether efficacy increases or decreases and on the agonist efficacy in the wild-type receptor. If the mutation shifts the equilibrium toward the open state of the bound receptor (as in our case), efficacy should increase, but an increase in the maximum agonist response would be noticeable only if the wild-type maximum open probability was well below 1, i.e. if the agonist is a partial agonist (21) . While little is known of the actual efficacy of nicotinic agonists on neuronal receptors, nicotine is a good example of a possible partial agonist on ␣3␤4, as it elicits a maximum response which is only 44.7 Ϯ 2.3% of that to ACh (see Fig. 2 ). The maximum response to nicotine (as a fraction of the ACh maximum) is nearly doubled by the mutation, fulfilling the prediction (see ␣3␤4␤3
WT versus ␣3␤4 ␤3
V273T in Table I and in Fig. 2 ). Clearly, changes in agonist channel block and in desensitization (following the V273T mutation) may contribute to this effect, and further work is necessary to exclude this possibility.
We have shown that the ␤3 subunit can be incorporated into a functional ␣3␤4␤3 recombinant nicotinic receptor. While ␤3 is expressed in several areas of the nervous system which lack ␣3 and ␤4, the ␤3 subunit is also abundant in sensory ganglia, which are rich in ␣3 and ␤4 subunits. The nicotinic receptors of sensory ganglia (which are potential targets for nicotinic analgesia (22)) may therefore have an ␣3␤4␤3 composition. The reporter mutation approach used here will allow rapid screening of other subunit combinations containing ␤3 and will establish which of these can form functional receptors. In addition, the optimal cRNA ratios needed to ensure that the majority of assembled receptors are triplets can be determined. Once combination and optimal conditions have been identified by expression of the mutant, the wild-type triplet can be expressed heterologously to characterize the pharmacological and biophysical properties of the resulting receptor. Furthermore, if in neuronal nicotinic receptors, as in muscle receptors, the EC 50 shift produced by the hydrophilic mutation in the middle of TM2 is proportional to the number of mutated subunits (15, 16) , this approach can also be extended to the question of the stoichiometry of triplet receptors. Finally, as the mid-TM2 Leu (or Val) motif is present in all subunits belonging to the 4-transmembrane domain receptor superfamily, the method can readily be extended to other receptor types. (n ϭ 5 for each combination; cRNA injection ratio 1:1:20 for both ␤3 WT and ␤3 V273T ). Each oocyte provided an ACh and a nicotine concentration-response curve. Data were fitted as in Fig. 1 , after normalization to the fitted maximum of the ACh concentration-response curve in each oocyte. Note the increase in the maximum response to nicotine (relative to the maximum ACh response) for ␣3␤4 ϩ ␤3
V273T (see Table I ). 
